Rho GDP‐dissociation inhibitor α is a potential prognostic biomarker and controls telomere regulation in colorectal cancer. Issue 7 (31st May 2017)

• Record Type: Journal Article
• Authors: Huang, Dandan; Lu, Weisi; Zou, Shaomin; Wang, Huaiming; Jiang, Yuanling; Zhang, Xiya; Li, Pengqing; Songyang, Zhou; Wang, Lei; Wang, Jianping; Huang, Junjiu; Fang, Lekun
• Is Part Of: Cancer science. Volume 108:Issue 7(2017)
• Page Start: 1293
• Page End: 1302
• Publication Date: 2017-05-31
• Subjects: Colorectal cancer -- prognosis -- RhoGDIα -- telomere -- TRF1; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.13259
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : Rho GDP‐dissociation inhibitor α (RhoGDIα) is an essential regulator for Rho GTPases. Although RhoGDI α may serve as an oncogene in colorectal cancer (CRC), the underlying mechanism is still unclear. We investigated the function, mechanism, and clinical significance of RhoGDIα in CRC progression. We founded that downregulation of RhoGDIα repressed CRC cell proliferation, motility, and invasion. Overexpression of RhoGDIα increased DNA damage response signals at telomeres, and led to telomere shortening in CRC cells, also being validated in 26 pairs of CRC tissues. Mechanistic studies revealed that RhoGDIα could promote telomeric repeat factor 1 (TRF1) expression through the phosphatidylinositol 3‐kinase–protein kinase B signal pathway. Moreover, RhoGDIα protein levels were strongly correlated with TRF1 in CRC tissues. A cohort of 297 CRC samples validated the positive relationship between RhoGDIα and TRF1, and revealed that RhoGDIα and TRF1 levels were negatively associated with CRC patients' survival. Taken together, our results suggest that RhoGDIα regulate TRF1 and telomere length and may be novel prognostic biomarkers in colorectal cancer. Abstract : RhoGDIα promotes colorectal tumorigenesis. RhoGDIα shortens telomere length and induces telomere dysfunction. RhoGDIα upregulates TRF1 through the PI3K‐Akt signaling pathway.